Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials
Gespeichert in:
| Veröffentlicht in: | Eye (London) 2022-04, Vol.36 (4), p.679-680 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 680 |
|---|---|
| container_issue | 4 |
| container_start_page | 679 |
| container_title | Eye (London) |
| container_volume | 36 |
| creator | Sharma, Ashish Kumar, Nilesh Parachuri, Nikulaa Karanam, Dhatri Kuppermann, Baruch D. Bandello, Francesco Regillo, Carl D. |
| description | |
| doi_str_mv | 10.1038/s41433-021-01831-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8956679</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2643140218</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-e0b5a6fac79e39a022d99d49986316b128942ddcecc11292a194739487eabff03</originalsourceid><addsrcrecordid>eNp9kU9PFTEUxRuDkQf6BVyQJmwei9H-m-l0Y2IQ9CUYXWDirul0bh8lM-2znSHRT0_xPQFZsLqL8zunvfcg9JaSd5Tw9n0WVHBeEUYrQltOK_ECLaiQTVWLWuyhBVE1qRhjP_fRQc7XhBRRkldonwtZDFwtUDw3yVs_mg5vrkwGzPGnr2d4St4MOPt18M5bEyzg6PAGUo7BDP4P9AUBM40QJuzDBOnGDBkvv1-uTnCCtR8Bu5iwm6c5wUNkfo1eujLgzW4eoh_nZ5enX6qLb59Xpx8vKiukmCogXW0aZ6xUwJUhjPVK9UKptuG06ShrlWB9b8FaSplihiohuRKtBNM5R_gh-rDN3czdCAUMUzKD3qSyavqto_H6fyX4K72ON7pVddNIVQKWu4AUf82QJz36bGEYTIA4Z81qRRlVTSsLevwEvY5zKncqVCM4FaWhtlBsS9kUc07g7j9Dib7rU2_71IXWf_vUopiOHq9xb_lXYAH4FshFCmtID28_E3sLthirrg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2643140218</pqid></control><display><type>article</type><title>Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><creator>Sharma, Ashish ; Kumar, Nilesh ; Parachuri, Nikulaa ; Karanam, Dhatri ; Kuppermann, Baruch D. ; Bandello, Francesco ; Regillo, Carl D.</creator><creatorcontrib>Sharma, Ashish ; Kumar, Nilesh ; Parachuri, Nikulaa ; Karanam, Dhatri ; Kuppermann, Baruch D. ; Bandello, Francesco ; Regillo, Carl D.</creatorcontrib><identifier>ISSN: 0950-222X</identifier><identifier>EISSN: 1476-5454</identifier><identifier>DOI: 10.1038/s41433-021-01831-4</identifier><identifier>PMID: 34718339</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/154/433 ; 631/154/51 ; Diabetic Retinopathy ; Editorial ; Humans ; Laboratory Medicine ; Macular Edema ; Medicine ; Medicine & Public Health ; Monoclonal antibodies ; Ophthalmology ; Pharmaceutical Sciences/Technology ; Precision Medicine ; Ranibizumab ; Surgery ; Surgical Oncology</subject><ispartof>Eye (London), 2022-04, Vol.36 (4), p.679-680</ispartof><rights>The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2021</rights><rights>The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-e0b5a6fac79e39a022d99d49986316b128942ddcecc11292a194739487eabff03</citedby><cites>FETCH-LOGICAL-c474t-e0b5a6fac79e39a022d99d49986316b128942ddcecc11292a194739487eabff03</cites><orcidid>0000-0002-7439-2081 ; 0000-0003-3238-9682 ; 0000-0002-8550-9791</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956679/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956679/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,41467,42536,51298,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34718339$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sharma, Ashish</creatorcontrib><creatorcontrib>Kumar, Nilesh</creatorcontrib><creatorcontrib>Parachuri, Nikulaa</creatorcontrib><creatorcontrib>Karanam, Dhatri</creatorcontrib><creatorcontrib>Kuppermann, Baruch D.</creatorcontrib><creatorcontrib>Bandello, Francesco</creatorcontrib><creatorcontrib>Regillo, Carl D.</creatorcontrib><title>Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials</title><title>Eye (London)</title><addtitle>Eye</addtitle><addtitle>Eye (Lond)</addtitle><subject>631/154/433</subject><subject>631/154/51</subject><subject>Diabetic Retinopathy</subject><subject>Editorial</subject><subject>Humans</subject><subject>Laboratory Medicine</subject><subject>Macular Edema</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Monoclonal antibodies</subject><subject>Ophthalmology</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Precision Medicine</subject><subject>Ranibizumab</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><issn>0950-222X</issn><issn>1476-5454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kU9PFTEUxRuDkQf6BVyQJmwei9H-m-l0Y2IQ9CUYXWDirul0bh8lM-2znSHRT0_xPQFZsLqL8zunvfcg9JaSd5Tw9n0WVHBeEUYrQltOK_ECLaiQTVWLWuyhBVE1qRhjP_fRQc7XhBRRkldonwtZDFwtUDw3yVs_mg5vrkwGzPGnr2d4St4MOPt18M5bEyzg6PAGUo7BDP4P9AUBM40QJuzDBOnGDBkvv1-uTnCCtR8Bu5iwm6c5wUNkfo1eujLgzW4eoh_nZ5enX6qLb59Xpx8vKiukmCogXW0aZ6xUwJUhjPVK9UKptuG06ShrlWB9b8FaSplihiohuRKtBNM5R_gh-rDN3czdCAUMUzKD3qSyavqto_H6fyX4K72ON7pVddNIVQKWu4AUf82QJz36bGEYTIA4Z81qRRlVTSsLevwEvY5zKncqVCM4FaWhtlBsS9kUc07g7j9Dib7rU2_71IXWf_vUopiOHq9xb_lXYAH4FshFCmtID28_E3sLthirrg</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Sharma, Ashish</creator><creator>Kumar, Nilesh</creator><creator>Parachuri, Nikulaa</creator><creator>Karanam, Dhatri</creator><creator>Kuppermann, Baruch D.</creator><creator>Bandello, Francesco</creator><creator>Regillo, Carl D.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7439-2081</orcidid><orcidid>https://orcid.org/0000-0003-3238-9682</orcidid><orcidid>https://orcid.org/0000-0002-8550-9791</orcidid></search><sort><creationdate>20220401</creationdate><title>Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials</title><author>Sharma, Ashish ; Kumar, Nilesh ; Parachuri, Nikulaa ; Karanam, Dhatri ; Kuppermann, Baruch D. ; Bandello, Francesco ; Regillo, Carl D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-e0b5a6fac79e39a022d99d49986316b128942ddcecc11292a194739487eabff03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>631/154/433</topic><topic>631/154/51</topic><topic>Diabetic Retinopathy</topic><topic>Editorial</topic><topic>Humans</topic><topic>Laboratory Medicine</topic><topic>Macular Edema</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Monoclonal antibodies</topic><topic>Ophthalmology</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Precision Medicine</topic><topic>Ranibizumab</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sharma, Ashish</creatorcontrib><creatorcontrib>Kumar, Nilesh</creatorcontrib><creatorcontrib>Parachuri, Nikulaa</creatorcontrib><creatorcontrib>Karanam, Dhatri</creatorcontrib><creatorcontrib>Kuppermann, Baruch D.</creatorcontrib><creatorcontrib>Bandello, Francesco</creatorcontrib><creatorcontrib>Regillo, Carl D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Eye (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sharma, Ashish</au><au>Kumar, Nilesh</au><au>Parachuri, Nikulaa</au><au>Karanam, Dhatri</au><au>Kuppermann, Baruch D.</au><au>Bandello, Francesco</au><au>Regillo, Carl D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials</atitle><jtitle>Eye (London)</jtitle><stitle>Eye</stitle><addtitle>Eye (Lond)</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>36</volume><issue>4</issue><spage>679</spage><epage>680</epage><pages>679-680</pages><issn>0950-222X</issn><eissn>1476-5454</eissn><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>34718339</pmid><doi>10.1038/s41433-021-01831-4</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-7439-2081</orcidid><orcidid>https://orcid.org/0000-0003-3238-9682</orcidid><orcidid>https://orcid.org/0000-0002-8550-9791</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-222X |
| ispartof | Eye (London), 2022-04, Vol.36 (4), p.679-680 |
| issn | 0950-222X 1476-5454 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8956679 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; PubMed Central |
| subjects | 631/154/433 631/154/51 Diabetic Retinopathy Editorial Humans Laboratory Medicine Macular Edema Medicine Medicine & Public Health Monoclonal antibodies Ophthalmology Pharmaceutical Sciences/Technology Precision Medicine Ranibizumab Surgery Surgical Oncology |
| title | Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T05%3A17%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Faricimab%20phase%203%20DME%20trial%20significance%20of%20personalized%20treatment%20intervals%20(PTI)%20regime%20for%20future%20DME%20trials&rft.jtitle=Eye%20(London)&rft.au=Sharma,%20Ashish&rft.date=2022-04-01&rft.volume=36&rft.issue=4&rft.spage=679&rft.epage=680&rft.pages=679-680&rft.issn=0950-222X&rft.eissn=1476-5454&rft_id=info:doi/10.1038/s41433-021-01831-4&rft_dat=%3Cproquest_pubme%3E2643140218%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2643140218&rft_id=info:pmid/34718339&rfr_iscdi=true |